Summary
Definition
History and exam
Key diagnostic factors
- permanência prévia em área endêmica
- imunossupressão
- febre prolongada
- perda de peso
- lesões cutâneas ulcerativas
- presença de fatores de risco
- vários nódulos cutâneos não ulcerativos
- inflamação destrutiva da mucosa
- esplenomegalia
- escurecimento da pele
Other diagnostic factors
- fadiga
- tosse
- cefaleia
- enfraquecimento
- linfonodos aumentados
- hepatomegalia
- tratamento antileishmaniose prévio
- epistaxe
- dor abdominal
Risk factors
- alta exposição a picadas de flebotomíneo
- pobreza
- proximidade com um paciente com uma história de infecção
- proprietário de animais domésticos
- imunossupressão
Diagnostic investigations
1st investigations to order
- Hemograma completo
- testes da função hepática e ureia/creatinina
- gonadotrofina coriônica humana (hCG) sérica
Investigations to consider
- exame microscópico do espécime relevante
- cultura de sangue (camada leucoplaquetária) ou tecido
- reação em cadeia da polimerase
- sorologia
- intradermorreação para leishmaniose (teste cutâneo de Montenegro)
- teste para sorologia de HIV
Treatment algorithm
leishmaniose cutânea (LC)
leishmaniose mucosa (LM)
leishmaniose visceral (LV)
leishmaniose dérmica pós-calazar (LDPC)
recidiva
Contributors
Authors
Naomi E. Aronson, MD
Professor of Medicine
Director, Infectious Diseases Division
Uniformed Services University of the Health Sciences
Bethesda
MD
Disclosures
NEA receives federal grants to study leishmaniasis (received by NEA's institution USU), has given lectures on the topic of leishmaniasis at national and international meetings, and has a patent on biomarkers for leishmaniasis. NEA has received honoraria from the Welcome Trust. NEA's institution USU has received royalties for her writing and editorial work for UpToDate. NEA is an author of a number of references cited in this topic. The views expressed in this topic are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, the Department of Defense, or the US Government.
Nathanial K. Copeland, MD, MTM&H
Assistant Professor of Medicine
Uniformed Services University of the Health Sciences
Bethesda
MD
Disclosures
NKC is an author of a number of references cited in this topic. The views expressed in this topic are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, the Department of Defense, or the US Government.
Acknowledgements
Professor Naomi E. Aronson and Dr Nathanial K. Copeland would like to gratefully acknowledge Professor Richard Reithinger and Professor François Chappuis, previous contributors to this topic.
Disclosures
RR and FC are authors of a number of references cited in this topic.
Peer reviewers
Roberto Arenas, MD
Chief of the Mycology Section
Dr. Manuel Gea Gonzalez General Hospital
Mexico
Disclosures
RA is the author of an article cited in this topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016 Dec 15;63(12):1539-57.Full text Abstract
Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. Infect Dis Clin North Am. 2019 Mar;33(1):101-17. Abstract
Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-70. Abstract
Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opin Pharmacother. 2019 Jul;20(10):1251-65. Abstract
Pan American Health Organization. Guideline for the treatment of Leishmaniasis in the Americas. Second edition. Sep 2022 [internet publication].Full text
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Leishmaniasis. 2017 [internet publication].Full text
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Esplenomegalia malárica hiper-reativa (HMS)
- Infecção malárica
- Esquistossomose
More DifferentialsGuidelines
- CDC Yellow Book: health information for international travel - visceral leishmaniasis
- Parasites - leishmaniasis. Resources for health professionals
More Guidelines
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer